Futura Medical (FRA:GYX) Total Assets: €5.97 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Futura Medical Total Assets?

Futura Medical FRA:GYX Total Assets is €5.97 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Futura Medical's Total Assets for the quarter that ended in Dec. 2025 was €5.97 Mil.

During the past 12 months, Futura Medical's average Total Assets Growth Rate was -74.00% per year. During the past 3 years, the average Total Assets Growth Rate was -9.40% per year. During the past 5 years, the average Total Assets Growth Rate was 36.20% per year. During the past 10 years, the average Total Assets Growth Rate was 12.30% per year.

During the past 13 years, Futura Medical's highest 3-Year average Total Assets Growth Rate was 89.70%. The lowest was -41.60%. And the median was 14.15%.

Total Assets is connected with ROA %. Futura Medical's annualized ROA % for the quarter that ended in Dec. 2025 was -91.48%. Total Assets is also linked to Revenue through Asset Turnover. Futura Medical's Asset Turnover for the quarter that ended in Dec. 2025 was 0.13.

Futura Medical  (FRA:GYX) Total Assets Explanation

Total Assets is connected with ROA %.

Futura Medical's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-5.682/( (6.456+5.967)/ 2 )
=-5.682/6.2115
=-91.48 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Futura Medical's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0.796/( (6.456+5.967)/ 2 )
=0.796/6.2115
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Futura Medical Total Assets Related Terms

Futura Medical Total Assets Historical Data

* Premium members only.

The historical data trend for Futura Medical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Futura Medical Total Assets Chart

Futura Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.89 7.44 13.72 16.41 5.97

Futura Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.72 11.19 16.41 6.46 5.97

Futura Medical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Futura Medical's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=3.207+2.76
=5.97

Futura Medical's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=3.207+2.76
=5.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of €5.97 Mil mean?
Futura Medical (FRA:GYX) has a Total Assets of €5.97 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Futura Medical and its competitors.
Is Futura Medical's Total Assets too high?
Futura Medical's current Total Assets is €5.97 Mil.
How does Futura Medical's Total Assets compare to VRTX and REGN?
Futura Medical's Total Assets of €5.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Futura Medical and its competitors. Futura Medical's current Total Assets is €5.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Futura Medical stock overvalued right now?
Based on GuruFocus' analysis, Futura Medical (FRA:GYX) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.00 — trading 95% below its estimated fair value. The current Total Assets is €5.97 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Futura Medical (FRA:GYX), the current Total Assets is €5.97 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Futura Medical Business Description

Other Exchanges FAMDF:USAFUMl:UKFUM:UK
Address 40 Occam Road, Surrey Technology Centre, Guildford, Surrey, GBR, GU2 7YG
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.